secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-153471
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica amends Torii deal: $8M milestone accelerated, $10M on Japan approval, $40M trial funding
--------------------------------------------------------------------------------

- Torii pays $8M milestone in July 2025 for starting global Phase 3 common warts trial of YCANTH.
- Torii to pay $10M cash upon Japanese approval of YCANTH for molluscum, expected by end-2025.
- Torii funds first $40M of trial costs (~90% of budget); Verrica repays via future royalties/transfer price.
- First patient dosing in U.S. Phase 3 common warts trial expected Q4 2025.
- OrbiMed waived going-concern qualification requirement under credit agreement for remainder of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525153471/0001193125-25-153471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525153471/d682251d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-153471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer